Company intelligence / Profile preview

BrainScan.ai

Ownership: Private
Development stage: Other

Overview

BrainScan.ai has developed and commercialized an AI-powered decision support system for the automated analysis of human brain CT scans. The CE MDR-certified product can detect, classify, and localize up to 20 different pathological changes in the brain—including hemorrhage and stroke—providing rapid results to radiologists via seamless PACS integration. Clinical validation studies have shown performance comparable to leading competitors in detecting intracranial hemorrhage.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Medical Imaging

Beyond the preview

Go deeper on BrainScan.ai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrainScan.ai.

Explore the full profile